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Summary
The purpose of the study was to investigate whether, on farms
with both post-weaning multisystemic wasting syndrome
(PMWS) and porcine reproductive and respiratory syndrome
(PRRS), the PRRS vaccination of sows and their fattening
pigs protects against these syndromes. In a farrow-to-ﬁnish pig
farm with a history of PRRS and PMWS, 200 gilts and sows
were allocated to one of two groups of equal size. The ﬁrst
group (C-sow group) was used as untreated controls, while the
animals of the second group (V-sow group) were vaccinated
with live Porcilis PRRS vaccine. At the next weaning, all
piglets of half the sows of the C sow group were vaccinated
once at 35 days of age with the vaccine (CV group), while the
oﬀspring of the other half of the unvaccinated sows were left
unvaccinated (CC group). Similarly, the oﬀspring of half the
sows of the V sow group were vaccinated (VV group), while
those of the other half of the vaccinated sows were left un-
vaccinated (VC group). No signiﬁcant diﬀerences in morbidity
were observed between the groups during the nursery and
ﬁnishing phases, while morbidity in the growers was signiﬁ-
cantly reduced in the CV- and VV-groups (P < 0.05).
Growers mortality was signiﬁcantly reduced after piglet
vaccination when compared with unvaccinated pigs of
unvaccinated dams (P < 0.05). Average daily gain and feed
conversion ratio were signiﬁcantly improved in vaccinated
piglets compared with those in the unvaccinated groups
(P < 0.05).
Introduction
Porcine reproductive and respiratory syndrome (PRRS) is a
viral disease caused by PRRS virus (PRRSV), a member of
the family Arteriviridae. It is characterized by reproductive
disorders in breeding pigs, and respiratory malfunction
mainly apparent in growing and fattening pigs (Keﬀaber,
1989; Polson et al., 1992; Meredith, 1995). The severity of
PRRSV infection can vary widely, ranging from an almost
complete lack of clinical signs to devastating outbreaks of
reproductive and respiratory disease (Benﬁeld et al., 1999).
Such variation also depends on the origin of the infective
strain as phylogenetic and pathogenetic diﬀerences have
been described between European and American clusters,
but also within each cluster (Wensvoort et al., 1992;
Murakami et al., 1994; Magar et al., 1995; Dea et al.,
1996; Labarque et al., 2004). Fundamental to the control
of PRRS is achievement of stability of the virus circulation
in the breeding herd as for instance by not introducing naı¨ve
gilts or by keeping a constant level of immunity (Dee and
Philips, 1999; Dee, 2003). One way of achieving this is by
vaccination of the breeding herd. It appears that vaccination
of the fattening pigs may also contribute to the stabilization
process. Protection conferred by the vaccines can be
variable, basically due to strain diﬀerences, but homogenous
vaccine strains nonetheless appear to provide good protec-
tion (Labarque et al., 2004).
Post-weaning multisystemic wasting syndrome (PMWS) is
another recently studied disease entity of swine associated with
porcine circovirus type 2 (PCV2). It is mostly observed in 5- to
12-week-old weaned pigs causing gradual loss of bodyweight,
pallor, dyspnoea and lymph node swelling with high levels of
morbidity, and high case fatality in acute cases (Lukert and
Allan, 1999).
In the ﬁeld, PRRSV and PCV2 are quite often found in the
same population (Rose et al., 2003; Ellis et al., 2004; Wellen-
berg et al., 2004). Experimental co-infection of conventional
pigs with the two agents has shown that PRRSV is the most
damaging of the two, causing severe disease, and that PMWS
can be reproduced in its most severe form when there is co-
infection with PRRSV (Rovira et al., 2002). However, the
eﬀect of vaccination against PRRSV in combined ﬁeld
infections is not yet known.
The aim of this study was to assess the eﬃcacy of
Porcilis PRRS, a live vaccine prepared from a European
strain of PRRSV, on the health status and productivity of
fattening pigs on a farm infected by both PRRSV and
PCV2.
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Materials and Methods
Trial farm
The trial was performed on an all-in, all-out farrow-to-ﬁnish
farm of 250 sows, producing approximately 4300–4500
fattening pigs per year. The farm was situated in an area of
high pig density, aﬀected by both PRRSV and PCV2
(Filippiada, Preveza, Greece). For at least 1 year prior to
the start of the trial, the farm was diagnosed as PRRS
positive, based on clinical signs (increased returns to oestrus,
small litters, weak piglets and increased piglet mortality) and
serology [speciﬁc antibody detecting immunoperoxidase
monolayer assay (IPMA) technique as described by Wens-
voort et al. (1991)].
The diagnosis of PMWS was conﬁrmed 1 month prior to the
start of the trial by speciﬁc clinical signs (wasting, apparent
lymphadenopathy, jaundice, pallor and tachypnea) in pigs at
7–11 weeks of age and by immuno-labelling techniques
in tissues from aﬀected pigs (immuno-histochemistry for
detecting the PCV2 antigen and in situ hybridization
for nucleic acid), as well as lymphoid depletion in lymphnodes
(Dr S. Kennedy, Veterinary Sciences Division, Department of
Agriculture and Rural Development, Belfast, UK).
Weaning took place weekly, at the age of 26 ± 2 days, in
batches of 85 (75–95) weaners in the ﬂat deck unit, and the
piglets were allocated to pens of 10–12 pigs according to sex
and weight. At 63 days of age, the pigs were moved into the
growing/ﬁnishing house, in pens of 10–12 animals, where they
remained until slaughter at the age of 23–24 weeks (95–100 kg
body weight). Growing lasted 7 weeks, and ﬁnishing 7–8 weeks
depending on the feed oﬀered.
The temperature and ventilation of all the houses was
controlled automatically. Farm personnel cleaned each pen
daily, and when empty, each pen was thoroughly cleaned and
disinfected, and then not re-stocked for 2–3 days.
The pigs were provided a home-mixed feed based on corn/
barley/wheat-soya meal, depending on the season. No anti-
microbials and/or growth promoters were used in any diet
during the trial.
All breeding pigs were vaccinated against Aujeszky’s disease
virus (ADV), swine inﬂuenza virus-SIV, parvovirus (PPV),
atrophic rhinitis (AR), Escherichia coli, Clostridium perfringens
and Erysipelothrix rhusiopathiae (SE). All fattening pigs were
vaccinated against Mycoplasma hyopneumoniae at 7 and
21 days of age, and against ADV and SIV at 90 days of age.
All sows were treated with a single ivermectin injection 14 days
prior to farrowing, for the control of endo/ectoparasites.
Ivermectin was also administered to the boars twice a year.
Routine Leptospira spp. serology was undertaken on blood
samples from pigs of all ages. Routine mycotoxicological
analysis (zearalenone, aﬂatoxins B1, B2, G1, G2, deoxynivalenol
(DON), 3-acetyl-DON, 15-acetyl-DON, nivalenol) was carried
out on all raw feed materials by the Veterin S.A. laboratory
(Aspropyrgos, Attiki, Greece).
Vaccines used in the trial
The attenuated DV strain of PRRSV (Porcilis PRRS;
Intervet, Boxmeer, the Netherlands) originating in Europe
was used. A single intramuscular dose contains ‡104.0 TCID50
suspended in 2 ml of a tocopherol-based adjuvant (Diluvac
Forte; Intervet).
Experimental protocol
In a previous study performed in the same trial farm
(Alexopoulos et al., 2005), two treatment groups, one with
100 Porcilis PRRS-vaccinated sows (V group) and another
with 100 non-vaccinated sows (C group) were observed for one
reproductive cycle. Sows were equally allocated in these groups
according to their bodyweight and their parity. They were
weekly entering the farrowing rooms alternately by group e.g.
they were housed separately (Alexopoulos et al., 2005). The
weaner pigs of these sows/gilts were further used in the current
study, in 20 sequential weekly batches.
The piglets of 50 litters of the C group of sows and of
50 litters of the V group of sows were left untreated (CC- and
VC-groups of piglets respectively), while the pigs of the rest of
the 50 litters of each of the C- and V-groups of sows, received
a single intramuscular dose of Porcilis PRRS vaccine at
roughly 5 weeks old. The piglets were ear-marked and were
grouped so that, all of the animals of one pen originated from
the same group of sows, and remained in the same group up to
the end of the experiment.
At the end of the trial, the C group comprised 662 pigs, and
the V group 826 piglets, 1488 in total.
Parameters recorded and calculated
Blood samples from 20 sows and 20 ﬁnishers had been
collected 1 month before the start of the trial and examined for
antibodies against a European PRRSV by indirect immuno-
ﬂuorescent assay in US- or EU-type PRRSV infected MA104
cells essentially as described by Yoon et al. (1995). A similar
sampling and examination had been repeated 4 months after
the start of the trial with 10 samples from each group of sows
and from 20 ﬁnishers at the slaughter age.
During the trial, all pigs were almost daily monitored for
signs of disease (loss of weight, visible lymphadenopathy of
inguinal lymphnodes, colour of skin and mucosae, respiratory
and enteric disorders, death) by the standard personnel of the
farm including a veterinarian.
Ten pens per group were selected so that each batch
contained an equal distribution by sex. Thus a total of 329
speciﬁcally identiﬁed pigs (65 from CC group, 82 from CV
group, 82 from VC group and 100 from VV group) were
included. All piglets of selected pens were weighed individually
at 26 days (weaning); 63 days (end of nursery period);
112 days (end of grower period) and 161 days (end of ﬁnisher
period). Feed consumption was recorded weekly, per pen, and
the average daily gain (ADG), the average daily feed intake
(ADFI) and the feed conversion ratio (FCR) were calculated.
Faecal material obtained from all diarrhoeic pigs was
submitted for laboratory examination to determine the pres-
ence of pathogens (coccidia, enterobacteriacae) essentially as
described elsewhere (Kritas et al., 2003).
Statistical analysis
Statistical analysis was carried out using the sas Statistical
Package (The SAS System release 6.12 for Windows 1996;
SAS Institute Inc., Cary, NC, USA). Each recorded param-
eter per group was subjected to analysis of variance using
the General Linear Models (GLM) procedure, with pen and
sex as co-variants. The Duncan’s multiple range test was
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used as the comparison test, to determine the statistical
diﬀerence between groups. The level of signiﬁcance was set
at P ¼ 0.05. Pearson chi-square analysis was used to
distinguish diﬀerences between groups for those parameters
expressed as frequencies.
Results
The serological examination of the blood samples from sows
and ﬁnishing pigs collected 1 month prior to the start of the
trial had shown that >80% of those tested were seropositive
for antibodies against a European PRRSV strain. The serology
from sows and ﬁnishers 4 months after the start of the trial
had shown prevalence of a European PRRSV strain in >80%
of the animals in both subpopulations of sows and in the
ﬁnishers.
As observed in both nursery and growers stage, morbidity
was signiﬁcantly lower in the PRRS-vaccinated pigs (CV- and
VV-groups) compared with the CC group, while that of the VC
group was at an intermediate level (Table 1). In all groups,
morbidity in the growing period was twice that observed in the
nursery period (Table 1).
The ﬁrst clinical cases were observed at the end of the
nursery stage and peaked during the growing stage. Wasting
was observed in >65% of sick animals in the nursery phase
and 95% of sick animals in the growing phase. Clinically
visible inguinal lymphadenopathy was observed at frequencies
ranging between 45% and 57% of the sick animals during the
nursery stage, and between 67% and 77% of the sick animals
during the growing stage. Pallor was observed in 20–57% of
the sick animals during the nursery and growing stages, while
the frequency of jaundice and unclassiﬁed diarrhoea occurred
less frequently (usually <20% of the sick animals). During the
ﬁnishing stage, cough and sometimes, soft feces were indicative
of enzootic pneumonia and ileitis, respectively, in aﬀected pigs.
PRRS-vaccinated pigs (CV- and VV-groups) showed a
signiﬁcantly reduced frequency of wasting compared with the
CC group, in both nursery and growing stages, while the
pattern of lymphadenopathy during the growing stage was
similar (P < 0.05). With respect to these signs, the frequency
in the pigs of the VC group did not diﬀer signiﬁcantly from
either the CC group or the CV- and VV-groups. Pallor was
markedly less frequent in growers of the VV group compared
with CC- and CV-groups.
Scours caused by E. coli were detected sporadically in a
small number of pigs (<2.5%) in all groups at the beginning of
the nursery stage. Laboratory examination showed about one
third of these cases were attributed to enterotoxigenic E. coli
F4 strains and a quarter of them to F5 strains. Some
unclassiﬁed diarrhoea was also detected in both nursery
(<1.1%) and growing stages (<3.6%).
Mortality was markedly increased during the growing stage
compared with the other stages. In that period, the CV group
of PRRS-vaccinated pigs exhibited mortality three times
lower, and the PRRS-vaccinated VV group, mortality eight
times lower than with the CC group (Table 2). Following
postmortem examination, two deaths during the nursery stage
(in CV- and VC-groups) were attributed to severe E. coli
infection, and one death during the ﬁnishing stage (in VV
group) was attributed to complicated M. hyopneumoniae
infection.
The VV pigs gained signiﬁcantly more weight daily through-
out all the fattening sub-periods compared with the pigs of the
CC group, the latter showing the least gain (P < 0.05)
(Table 3). When ADG was calculated for the entire fattening
period, the pigs of the VV group were the best performers,
followed by those of the CV group (P < 0.05) and to a lesser
degree those of the VC group (P > 0.05). The vaccinated
piglets in CV- and VV-groups were signiﬁcantly heavier (3.3
and 4.4 kg respectively) at the end of the ﬁnishing stage than
those of the CC group (P < 0.05).
The pigs of all groups had similar ADFI during all the sub-
periods (P > 0.05). However, the FCR in the VV group was
the most signiﬁcantly improved during each stage as well as
over the entire fattening period, when compared with the CC
group, followed by the CV group (P < 0.05). The VC group
also showed improvement of FCR during some stages, but this
was less than those of VV- and CV-groups (Table 3).
Discussion
Several researchers have studied dual infections of PRRSV
with other pathogens (swine inﬂuenza virus, Hemophilus
parasuis, Actinobacillus pleuropneumoniae, Pasteurella multocida)
and have concluded that the clinical expression of combined
infections is more pronounced than that observed by either
pathogen alone (Carvalho et al., 1997; Pol et al., 1997;
Solano et al., 1997; Van Reeth et al., 2001). This seems
reasonable as PRRSV aﬀects alveolar macrophages and
interferes with local immunity, thus facilitating secondary
Table 1. Morbidity (loss of weight, visible lymphadenopathy of
inguinal lymphnodes, colour of skin and mucosae, respiratory and
enteric disorders, other) across the experimental groups
Number of sick pigs/number of total pigs (%)
CC* CV VC VV
NS** 35/282 (12.4)a 21/380 (5.5)b 31/399 (7.8)ab 14/427 (3.3)b
GS 70/277 (25.3)a 42/376 (11.2)b 63/394 (16.0)ab 34/426 (8.0)b
FS 9/245 (3.7)a 4/361 (1.1)a 10/360 (2.8)a 3/420 (0.7)a
*Explanation of piglet groups: CC, both mother and piglet unvacci-
nated; CV, mother unvaccinated/piglet vaccinated; VC, mother vac-
cinated/piglet unvaccinated; VV, both mother and piglet vaccinated.
**NS, nursery stage (26–63 days); GS, growing stage (64–112 days);
FS, ﬁnishing stage (113–161 days).
a,bMean values within the same row, with diﬀerent superscripts, diﬀer
signiﬁcantly (P < 0.05).
Table 2. Mortality across the experimental groups
Number of dead pigs/number of total pigs (%)
CC* CV VC VV
NS** 5/282 (1.8)a 4/380 (1.1)a 5/399 (1.3)a 1/427 (0.2)a
GS 32/277 (11.6)a 15/376 (4.0)b 34/394 (8.7)ab 6/426 (1.4)b
FS 1/245 (0.4)a 0/361 (0.0)a 0/360 (0.00)a 1/420 (0.2)a
*Explanation of piglet groups: CC, both mother and piglet unvacci-
nated; CV, mother unvaccinated/piglet vaccinated; VC, mother vac-
cinated/piglet unvaccinated; VV, both mother and piglet vaccinated.
**NS, nursery stage (26–63 days); GS, growing stage (64–112 days);
FS, ﬁnishing stage (113–161 days).
a,bMean values within the same row, with diﬀerent superscripts, diﬀer
signiﬁcantly (P < 0.05).
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infections (Benﬁeld et al., 1999). As PRRS and PCV2 viruses
are widespread in several areas worldwide, it is not uncom-
mon to ﬁnd both infections in the same populations at the
same time (Rose et al., 2003; Ellis et al., 2004; Wellenberg
et al., 2004). In a previous trial, performed on the same farm,
the eﬃcacy of Porcilis PRRS, was investigated with respect
to sow performance (Alexopoulos et al., 2005). In that study,
the beneﬁcial eﬀect of PRRS vaccination was demonstrated
by fewer pre-mature farrowings and returns-to-oestrus, less
culling, a lower incidence of postpartum dysgalactia syn-
drome, and by better farrowing rates, and greater numbers of
pigs born alive and weaned per litter. Many of these eﬀects
explain the large diﬀerence in the starting numbers of weaned
pigs between the groups of unvaccinated and vaccinated sows
at the start of this study (662 and 826 weaned pigs
respectively). Diﬀerences between CC- and CV-groups, or
VC- and VV-groups were mainly due to meeting the parity
requirement during allocation to the experimental groups.
Although no sequencing data showing homology between the
farm and vaccine strain were available, evidence for the
dominance of an European strain in the farm and equally to
both groups was, at least, convincing by indirect immuno-
ﬂuorescent examination.
The beneﬁcial eﬀect of Porcilis PRRS vaccine against the
respiratory manifestations of the syndrome has already been
documented in the fattening pigs of a PRRS-infected farm
(Mavromatis et al., 1999). Vaccinated pigs tended to have a
more rapid antibody response, and they showed reduced
morbidity and mortality, with a lower incidence of respiratory
bacterial infection compared with untreated pigs. In the
present study, reduced morbidity and mortality was also
observed in the vaccinated pigs (CV- and VV-groups) com-
pared with the unvaccinated ones (CC- and VC-groups),
suggesting that in dual infected farms, PRRSV still plays a
major role in the clinical manifestation during the fattening
stages, and needs to be controlled on such farms. Several
clinical signs observed mainly at the end of the nursery stage
and during the growing stage were compatible with those seen
in PMWS. PRRS vaccination had also reduced some of these
signs, a ﬁnding showing the close interaction that these two
pathogens might have in the ﬁeld. Reducing both PRRS and
PMWS on the farm means reduced treatment costs and lower
capital losses for the enterprise. Unfortunately as vaccine
strain is not marked, it was not possible to exclude spread of
the attenuated strain between groups of pigs, but only to avoid
mechanical spread or spread by not mixing pigs, or mostly by
placing groups in diﬀerent airspace.
Growth parameters are not only useful for monitoring
economic performance but also for the evaluation of animal
health, particularly in diseases of a chronic or mild character in
which visible clinical signs are absent. In this study, body-
weight, ADG and FCR of treated animals were greatly
improved compared with the untreated CC group. It was also
possible to rank the groups, with the VV group being the best
performer (improvements of 5.0% in BW, 5.4% in ADG and
5.6% in FCR), followed by the CV group (improvements of
3.7% in BW, 4.1% in ADG and 4.6% in FCR) (P < 0.05) and
to a lesser degree the VC group (improvements of 2.2% in BW,
2.3% in ADG and 2.3% in FCR) (P > 0.05), when compared
with the CC group. Since vaccination of sows conferred a
beneﬁcial eﬀect on their oﬀspring (Alexopoulos et al., 2005),
and as vaccination of young pigs (e.g. CV group) improves
Table 3. Growth performance in the groups of pigs at diﬀerent stages
Time point or period
Growth parameter
CC* CV VC VV
[Average bodyweight (kg)] ± SD
Weaning day 7.52a ± 0.39 7.50a ± 0.35 7.52a ± 0.40 7.52a ± 0.37
End of NS** 23.46a ± 2.20 23.92ab ± 1.77 24.14b ± 1.82 24.22b ± 1.46
End of GS 48.86a ± 5.54 50.85b ± 4.82 50.07ab ± 4.13 51.17b ± 4.10
End of FS 88.66a ± 9.57 91.94b ± 8.41 90.57ab ± 7.09 93.05b ± 7.45
[Average daily gain (kg)] ± SD
NS 0.455a ± 0.063 0.469ab ± 0.050 0.475b ± 0.053 0.477b ± 0.042
GS 0.519a ± 0.094 0.550b ± 0.083 0.530ab ± 0.072 0.550b ± 0.076
FS 0.812a ± 0.095 0.839ab ± 0.090 0.826ab ± 0.077 0.854b ± 0.084
TP 0.610a ± 0.071 0.635b ± 0.063 0.624ab ± 0.054 0.643b ± 0.056
[Average daily feed intake (kg)] ± SD
NS 0.664ab ± 0.112 0.672a ± 0.009 0.669ab ± 0.010 0.661b ± 0.005
GS 1.603a ± 0.008 1.591a ± 0.010 1.608a ± 0.026 1.591a ± 0.008
FS 2.988a ± 0.013 2.974a ± 0.015 2.981a ± 0.020 2.977a ± 0.007
TP 1.866a ± 0.009 1.859a ± 0.010 1.868a ± 0.010 1.857a ± 0.006
Feed conversion ratio ± SD
NS 1.46a ± 0.07 1.43ab ± 0.05 1.41b ± 0.03 1.38b ± 0.04
GS 3.10a ± 0.16 2.89b ± 0.11 3.04a ± 0.09 2.90b ± 0.09
FS 3.68a ± 0.09 3.54bc ± 0.11 3.61ab ± 0.07 3.48c ± 0.08
TP 3.06a ± 0.08 2.92b ± 0.09 2.99a ± 0.04 2.89b ± 0.05
*Explanation of piglet groups: CC, both mother and piglet unvaccinated; CV, mother unvaccinated/piglet vaccinated; VC, mother vaccinated/
piglet unvaccinated; VV, both mother and piglet vaccinated.
**NS, nursery stage (26–63 days); GS, growing stage (64–112 days); FS, ﬁnishing stage (113–161 days).
Mean values within the same row, with diﬀerent superscripts, diﬀer signiﬁcantly (P < 0.05).
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their health and productivity, it seems reasonable that, in
PRRSV- and PCV-2-infected farms, vaccination of both sows
and their oﬀspring produces an almost additive eﬀect in
delivering the best health and productivity results.
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